Anti-Glomerular Basement Membrane Disease

• Published in: Clinical journal of the American Society of Nephrology Vol. 12; no. 7; pp. 1162 - 1172
• Main Authors: McAdoo, Stephen P., Pusey, Charles D.
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 07.07.2017
• Subjects: Animals; Anti-Glomerular Basement Membrane Disease - diagnosis; Anti-Glomerular Basement Membrane Disease - epidemiology; Anti-Glomerular Basement Membrane Disease - immunology; Anti-Glomerular Basement Membrane Disease - therapy; Autoantibodies - immunology; Autoimmunity; Glomerular Diseases: Update for the Clinician; Humans; Immunosuppressive Agents - therapeutic use; Kidney Glomerulus - drug effects; Kidney Glomerulus - immunology; Kidney Glomerulus - pathology; Kidney Transplantation; Plasma Exchange; Predictive Value of Tests; Recurrence; Risk Factors; Steroids - therapeutic use; Treatment Outcome; Autoimmunity; Glomerulonephritis; Recurrence; Nephritis; Autoantibodies; Prognosis; vasculitis; Humans; Immunology and pathology; kidney transplantation; Autoantigens; Inflammation; Plasma Exchange; Hereditary; Plasmapheresis; Anti-Glomerular Basement Membrane Disease; kidney; Renal Insufficiency; Membranous; Glomerular Basement Membrane; Retrospective Studies; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Capillaries; renal dialysis
• ISSN: 1555-9041; 1555-905X; 1555-905X
• DOI: 10.2215/CJN.01380217

Anti–glomerular basement membrane (anti-GBM) disease is a rare small vessel vasculitis that affects the capillary beds of the kidneys and lungs. It is an archetypic autoimmune disease, caused by the development of directly pathogenic autoantibodies targeting a well characterized autoantigen expressed in the basement membranes of these organs, although the inciting events that induce the autoimmune response are not fully understood. The recent confirmation of spatial and temporal clustering of cases suggests that environmental factors, including infection, may trigger disease in genetically susceptible individuals. The majority of patients develop widespread glomerular crescent formation, presenting with features of rapidly progressive GN, and 40%–60% will have concurrent alveolar hemorrhage. Treatment aims to rapidly remove pathogenic autoantibody, typically with the use of plasma exchange, along with steroids and cytotoxic therapy to prevent ongoing autoantibody production and tissue inflammation. Retrospective cohort studies suggest that when this combination of treatment is started early, the majority of patients will have good renal outcome, although presentation with oligoanuria, a high proportion of glomerular crescents, or kidney failure requiring dialysis augur badly for renal prognosis. Relapse and recurrent disease after kidney transplantation are both uncommon, although de novo anti-GBM disease after transplantation for Alport syndrome is a recognized phenomenon. Copresentation with other kidney diseases such as ANCA-associated vasculitis and membranous nephropathy seems to occur at a higher frequency than would be expected by chance alone, and in addition atypical presentations of anti-GBM disease are increasingly reported. These observations highlight the need for future work to further delineate the immunopathogenic mechanisms of anti-GBM disease, and how to better refine and improve treatments, particularly for patients presenting with adverse prognostic factors.